Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234252 | 0.95 | LMNA (0.36) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL27832494 | 0.89 | LMNA (0.42) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL9476977 | 0.89 | LMNA (0.42) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL6419814 | 0.88 | ALDH1A1 (0.40) | LMNAL3MBTL1TDP1USP2 | |
| SCHEMBL8060427 | 0.88 | ALDH1A1 (0.40) | LMNAL3MBTL1TDP1USP2 | |
| SCHEMBL10423946 | 0.88 | ALDH1A1 (0.40) | LMNAL3MBTL1TDP1USP2 | |
| SCHEMBL15436121 | 0.87 | USP2 (0.40) | LMNAL3MBTL1KDM4EUSP2 | |
| SCHEMBL5795950 | 0.87 | USP2 (0.40) | LMNAL3MBTL1KDM4EUSP2 | |
| SCHEMBL21645278 | 0.87 | USP2 (0.40) | LMNAL3MBTL1KDM4EUSP2 | |
| SCHEMBL15648022 | 0.87 | USP2 (0.40) | LMNAL3MBTL1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177981-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2021-06-17 | — | — | US | claimed |
| EP-3740212-A2 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | Merck Sharp & Dohme Corp. (US) | 2020-11-25 | — | — | EP | claimed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | claimed |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12427187-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4436610-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024102633-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | MERCK SHARP & DOHME LLC (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023091441-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20130131310-A1 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. | 2013-05-23 | — | — | US | disclosed |
| WO-2012015681-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015687-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. | 2011-12-08 | — | — | US | disclosed |
| EP-2391646-A1 | CRYSTALLINE INSULIN-CONJUGATES | Smartcells, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110281791-A1 | CRYSTALLINE INSULIN-CONJUGATES | SMARTCELLS, INC. | 2011-11-17 | — | — | US | disclosed |
| WO-2010088300-A1 | CRYSTALLINE INSULIN-CONJUGATES | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-1663195-B1 | TAURINE BROMAMINE FOR INHIBITING PATHOGENIC BACTERIA AND FUNGI GROWTH AS WELL AS IN A MICROBICIDAL COMPOSITION | MARCINKIEWICZ JANUSZ (PL) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177981-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | GPR119, INSR, IGF1R | LMNA 2735/4885L3MBTL1 1417/4885TDP1 4669/4885 |
| US-12427187-B2 | Glucose-responsive insulin conjugates | GPR119, IRS1, INSR | LMNA 4836/4885L3MBTL1 1420/4885TDP1 4020/4885 |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | GPR119, INSR, IGF1R | LMNA 2410/4885L3MBTL1 1567/4885TDP1 4755/4885 |
| US-20110301083-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | LMNA 3842/4885L3MBTL1 3063/4885TDP1 3303/4885 |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | LMNA 4564/4885L3MBTL1 2640/4885TDP1 4160/4885 |
| US-20110281791-A1 | CRYSTALLINE INSULIN-CONJUGATES | IAPP, INSR, GPR119 | LMNA 1885/4885L3MBTL1 3901/4885TDP1 3291/4885 |
| US-20130131310-A1 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | ALK, ABL1, ERBB3 | LMNA 2138/4885L3MBTL1 2747/4885TDP1 1575/4885 |
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | GPR119, INSR, IAPP | LMNA 4837/4885L3MBTL1 1842/4885TDP1 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.